GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » EQL Pharma AB (FRA:7JK) » Definitions » EV-to-FCF

EQL Pharma AB (FRA:7JK) EV-to-FCF : -122.64 (As of May. 26, 2024)


View and export this data going back to 2021. Start your Free Trial

What is EQL Pharma AB EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, EQL Pharma AB's Enterprise Value is €127.42 Mil. EQL Pharma AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was €-1.04 Mil. Therefore, EQL Pharma AB's EV-to-FCF for today is -122.64.

The historical rank and industry rank for EQL Pharma AB's EV-to-FCF or its related term are showing as below:

FRA:7JK' s EV-to-FCF Range Over the Past 10 Years
Min: -283.32   Med: -5.85   Max: 283.17
Current: -121.24

During the past 12 years, the highest EV-to-FCF of EQL Pharma AB was 283.17. The lowest was -283.32. And the median was -5.85.

FRA:7JK's EV-to-FCF is ranked worse than
100% of 525 companies
in the Drug Manufacturers industry
Industry Median: 24.52 vs FRA:7JK: -121.24

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-26), EQL Pharma AB's stock price is €3.71. EQL Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €0.087. Therefore, EQL Pharma AB's PE Ratio for today is 42.64.


EQL Pharma AB EV-to-FCF Historical Data

The historical data trend for EQL Pharma AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EQL Pharma AB EV-to-FCF Chart

EQL Pharma AB Annual Data
Trend Dec14 Dec15 Dec16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -33.25 241.77 47.41 59.11 -111.31

EQL Pharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.11 -64.98 -113.99 -22.58 -111.31

Competitive Comparison of EQL Pharma AB's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, EQL Pharma AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EQL Pharma AB's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, EQL Pharma AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where EQL Pharma AB's EV-to-FCF falls into.



EQL Pharma AB EV-to-FCF Calculation

EQL Pharma AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=127.423/-1.039
=-122.64

EQL Pharma AB's current Enterprise Value is €127.42 Mil.
EQL Pharma AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EQL Pharma AB  (FRA:7JK) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

EQL Pharma AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.71/0.087
=42.64

EQL Pharma AB's share price for today is €3.71.
EQL Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.087.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


EQL Pharma AB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of EQL Pharma AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


EQL Pharma AB (FRA:7JK) Business Description

Traded in Other Exchanges
Address
Stortorget 1, 3rd Floor, Lund, SWE, 222 23
EQL Pharma AB is a pharmaceutical company engaged in developing and selling medicines to pharmacies and hospitals. The products offered by the company include generics and parallel imports. It operates and markets products to Nordic countries of Sweden, Denmark, Finland and Norway.

EQL Pharma AB (FRA:7JK) Headlines

No Headlines